CA2884873C - Improved methods for the acylation of maytansinol - Google Patents

Improved methods for the acylation of maytansinol Download PDF

Info

Publication number
CA2884873C
CA2884873C CA2884873A CA2884873A CA2884873C CA 2884873 C CA2884873 C CA 2884873C CA 2884873 A CA2884873 A CA 2884873A CA 2884873 A CA2884873 A CA 2884873A CA 2884873 C CA2884873 C CA 2884873C
Authority
CA
Canada
Prior art keywords
formula
compound
carboxyanhydride
reaction mixture
maytansinol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2884873A
Other languages
English (en)
French (fr)
Other versions
CA2884873A1 (en
Inventor
Wayne C. Widdison
Robert Yongxin Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunogen Inc
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Priority to CA3133906A priority Critical patent/CA3133906C/en
Publication of CA2884873A1 publication Critical patent/CA2884873A1/en
Application granted granted Critical
Publication of CA2884873C publication Critical patent/CA2884873C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01R—ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS
    • H01R12/00—Structural associations of a plurality of mutually-insulated electrical connecting elements, specially adapted for printed circuits, e.g. printed circuit boards [PCB], flat or ribbon cables, or like generally planar structures, e.g. terminal strips, terminal blocks; Coupling devices specially adapted for printed circuits, flat or ribbon cables, or like generally planar structures; Terminals specially adapted for contact with, or insertion into, printed circuits, flat or ribbon cables, or like generally planar structures
    • H01R12/50—Fixed connections
    • H01R12/51—Fixed connections for rigid printed circuits or like structures
    • H01R12/55—Fixed connections for rigid printed circuits or like structures characterised by the terminals
    • H01R12/58—Fixed connections for rigid printed circuits or like structures characterised by the terminals terminals for insertion into holes
    • H01R12/585—Terminals having a press fit or a compliant portion and a shank passing through a hole in the printed circuit board
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K1/00—Printed circuits
    • H05K1/02—Details
    • H05K1/0201—Thermal arrangements, e.g. for cooling, heating or preventing overheating
    • H05K1/0203—Cooling of mounted components
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K1/00—Printed circuits
    • H05K1/02—Details
    • H05K1/11—Printed elements for providing electric connections to or between printed circuits
    • H05K1/115—Via connections; Lands around holes or via connections
    • H05K1/116—Lands, clearance holes or other lay-out details concerning the surrounding of a via
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K1/00—Printed circuits
    • H05K1/18—Printed circuits structurally associated with non-printed electric components
    • H05K1/181—Printed circuits structurally associated with non-printed electric components associated with surface mounted components

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyamides (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2884873A 2012-09-26 2013-09-26 Improved methods for the acylation of maytansinol Active CA2884873C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3133906A CA3133906C (en) 2012-09-26 2013-09-26 Improved methods for the acylation of maytansinol

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705731P 2012-09-26 2012-09-26
US61/705,731 2012-09-26
PCT/US2013/061839 WO2014052537A1 (en) 2012-09-26 2013-09-26 Improved methods for the acylation of maytansinol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3133906A Division CA3133906C (en) 2012-09-26 2013-09-26 Improved methods for the acylation of maytansinol

Publications (2)

Publication Number Publication Date
CA2884873A1 CA2884873A1 (en) 2014-04-03
CA2884873C true CA2884873C (en) 2021-11-23

Family

ID=49328648

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2884873A Active CA2884873C (en) 2012-09-26 2013-09-26 Improved methods for the acylation of maytansinol
CA3133906A Active CA3133906C (en) 2012-09-26 2013-09-26 Improved methods for the acylation of maytansinol

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3133906A Active CA3133906C (en) 2012-09-26 2013-09-26 Improved methods for the acylation of maytansinol

Country Status (27)

Country Link
US (9) US9012629B2 (https=)
EP (3) EP3904358A1 (https=)
JP (7) JP6517693B2 (https=)
CN (2) CN104768955B (https=)
AU (4) AU2013323572B2 (https=)
BR (2) BR122021022582B1 (https=)
CA (2) CA2884873C (https=)
CY (2) CY1121415T1 (https=)
DK (2) DK2900676T3 (https=)
ES (2) ES2880754T3 (https=)
HR (2) HRP20190473T1 (https=)
HU (2) HUE043285T2 (https=)
IL (2) IL237899A (https=)
LT (2) LT2900676T (https=)
MX (2) MX366701B (https=)
MY (1) MY169250A (https=)
NZ (2) NZ739573A (https=)
PL (2) PL3486248T3 (https=)
PT (2) PT3486248T (https=)
RS (2) RS58493B1 (https=)
RU (2) RU2648992C2 (https=)
SG (1) SG11201501918UA (https=)
SI (2) SI3486248T1 (https=)
SM (2) SMT202100390T1 (https=)
TR (1) TR201903625T4 (https=)
WO (1) WO2014052537A1 (https=)
ZA (1) ZA201501898B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2900676T (lt) * 2012-09-26 2019-03-25 Immunogen, Inc. Maitanzinolio acilinimo patobulintas būdas
CN105585579A (zh) * 2014-10-24 2016-05-18 南京联宁生物制药有限公司 一种化合物及其制备方法以及美登素dm1的制备方法
JP6649961B2 (ja) * 2015-03-17 2020-02-19 レゲネロン ファーマシューティカルス，インコーポレーテッド アミノ酸アシル化試薬及びその使用方法
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
DK3956332T3 (da) 2019-04-18 2023-05-01 Indena Spa Diasteroselektiv fremgangsmåde til fremstilling af thiol- eller disulfid-holdige maytansionidestere og mellemprodukter deraf
US12473579B2 (en) 2019-11-29 2025-11-18 Microbiopharm Japan Co., Ltd. Method for enzymatically producing maytansinol
EP4685150A1 (en) 2023-04-28 2026-01-28 Chugai Seiyaku Kabushiki Kaisha Method for producing amide group-containing compound using n-carboxyamino acid anhydride

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
JPS6034556B2 (ja) * 1977-03-31 1985-08-09 武田薬品工業株式会社 抗生物質ｃ−１５００３
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5622790A (en) * 1979-07-31 1981-03-03 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JP3054741B2 (ja) * 1989-09-29 2000-06-19 武田薬品工業株式会社 Ｔａｎ―１３１３およびそのアシル誘導体
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
AU775373B2 (en) * 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
TWI298067B (en) * 2002-01-31 2008-06-21 Daiso Co Ltd New optically active compound, method for kinetic resolution of carbonic acid derivatives and catalyst thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
PL3524611T3 (pl) * 2003-05-20 2021-06-14 Immunogen, Inc. Udoskonalone czynniki cytotoksyczne zawierające nowe maitansynoidy
CA2536378A1 (en) 2003-08-22 2005-03-10 Activbiotics, Inc. Rifamycin analogs and uses thereof
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
PL1819359T3 (pl) * 2004-12-09 2015-08-31 Janssen Biotech Inc Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
US7301019B2 (en) * 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
WO2007011721A1 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
WO2007021674A2 (en) 2005-08-09 2007-02-22 Millennium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
CA2668134A1 (en) * 2006-11-06 2008-05-15 Teva Gyogyszergyar Zartkoerueen Muekoedoe Reszvenytarsasag Ascomycin and pimecrolimus having reduced levels of des-methylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
JP2008288289A (ja) 2007-05-16 2008-11-27 Oki Electric Ind Co Ltd 電界効果トランジスタとその製造方法
BRPI1010620B8 (pt) 2009-06-03 2021-05-25 Immunogen Inc métodos de conjugação
WO2011051960A2 (en) * 2009-09-25 2011-05-05 Cadila Healthcare Limited Process for the preparation of rapamycin derivatives
JP5889912B2 (ja) * 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
LT2900676T (lt) 2012-09-26 2019-03-25 Immunogen, Inc. Maitanzinolio acilinimo patobulintas būdas

Also Published As

Publication number Publication date
US9796731B2 (en) 2017-10-24
US10461449B2 (en) 2019-10-29
CN104768955A (zh) 2015-07-08
RU2018109295A3 (https=) 2021-06-24
CA2884873A1 (en) 2014-04-03
RU2018109295A (ru) 2019-02-26
RU2015111635A (ru) 2016-11-20
BR112015006505B1 (pt) 2022-03-15
JP2022068367A (ja) 2022-05-09
NZ706019A (en) 2018-03-23
JP2018109044A (ja) 2018-07-12
US10100062B2 (en) 2018-10-16
CN108586487B (zh) 2021-11-05
TR201903625T4 (tr) 2019-04-22
EP3486248A1 (en) 2019-05-22
MX390615B (es) 2025-03-20
CY1124337T1 (el) 2022-07-22
WO2014052537A1 (en) 2014-04-03
AU2022201557A1 (en) 2022-03-31
JP2024010055A (ja) 2024-01-23
AU2018201392A1 (en) 2018-03-15
NZ739573A (en) 2019-11-29
PL3486248T3 (pl) 2021-10-25
CN108586487A (zh) 2018-09-28
AU2020203823A1 (en) 2020-07-02
JP2020117527A (ja) 2020-08-06
US20140142297A1 (en) 2014-05-22
AU2020203823B2 (en) 2021-12-09
EP3904358A1 (en) 2021-11-03
IL237899A (en) 2017-08-31
PT3486248T (pt) 2021-07-12
SMT201900170T1 (it) 2019-05-10
IL253988B (en) 2019-02-28
HK1212341A1 (en) 2016-06-10
PL2900676T3 (pl) 2019-06-28
JP6735000B1 (ja) 2020-08-05
US20240145953A1 (en) 2024-05-02
US20170137440A1 (en) 2017-05-18
HRP20211030T1 (hr) 2021-10-01
RS62075B1 (sr) 2021-07-30
BR112015006505A2 (pt) 2017-07-04
CY1121415T1 (el) 2020-05-29
PT2900676T (pt) 2019-03-29
JP6517693B2 (ja) 2019-05-22
DK3486248T3 (da) 2021-07-12
EP2900676A1 (en) 2015-08-05
RS58493B1 (sr) 2019-04-30
MX2019008652A (es) 2019-09-13
US10944190B2 (en) 2021-03-09
RU2765072C2 (ru) 2022-01-25
CA3133906A1 (en) 2014-04-03
ES2880754T3 (es) 2021-11-25
IL253988A0 (en) 2017-10-31
MY169250A (en) 2019-03-19
AU2013323572A1 (en) 2015-04-02
SMT202100390T1 (it) 2021-09-14
ZA201501898B (en) 2019-06-26
AU2018201392B2 (en) 2020-03-12
US9469655B2 (en) 2016-10-18
CN104768955B (zh) 2018-04-27
US20190013604A1 (en) 2019-01-10
LT2900676T (lt) 2019-03-25
HUE043285T2 (hu) 2019-08-28
SI3486248T1 (sl) 2021-10-29
US9012629B2 (en) 2015-04-21
JP2025098242A (ja) 2025-07-01
US20180099980A1 (en) 2018-04-12
AU2013323572B2 (en) 2017-12-07
EP2900676B1 (en) 2018-12-19
US20150191488A1 (en) 2015-07-09
BR122021022582B1 (pt) 2023-01-10
HUE055443T2 (hu) 2021-11-29
JP2020180150A (ja) 2020-11-05
SI2900676T1 (sl) 2019-04-30
CA3133906C (en) 2023-05-02
MX366701B (es) 2019-07-22
EP3486248B1 (en) 2021-04-07
HRP20190473T1 (hr) 2019-05-03
SG11201501918UA (en) 2015-05-28
US20200153130A1 (en) 2020-05-14
US20240313444A1 (en) 2024-09-19
US20250007192A1 (en) 2025-01-02
LT3486248T (lt) 2021-08-25
MX2015003745A (es) 2015-06-24
JP2016500657A (ja) 2016-01-14
RU2648992C2 (ru) 2018-03-29
DK2900676T3 (en) 2019-04-08
ES2716561T3 (es) 2019-06-13

Similar Documents

Publication Publication Date Title
AU2020203823B2 (en) Improved methods for the acylation of maytansinol
HK40061916A (en) Improved methods for the acylation of maytansinol
HK40008930B (en) Improved methods for the acylation of maytansinol
HK40008930A (en) Improved methods for the acylation of maytansinol
HK1212341B (en) Improved method for the acylation of maytansinol

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180925

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240920

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240920

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240920

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250811

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251008